Background-Myocardial infarct size is a major determinant of left ventricular (LV) remodeling after ST-segment-elevation myocardial infarction. We evaluated whether LV global longitudinal strain (GLS), proposed as a novel marker of infarct size, is associated with 3-and 6-month LV dilatation after ST-segment-elevation myocardial infarction. Methods and Results-In the first ST-segment-elevation myocardial infarction patients treated with primary percutaneous coronary intervention, baseline LVGLS was measured with 2-dimensional speckle-tracking echocardiography.
M yocardial infarct size is a major determinant of subsequent left ventricular (LV) remodeling and dysfunction, both strong predictors of poor outcomes after ST-segmentelevation myocardial infarction (STEMI). [1] [2] [3] Assessment of infarct size can be achieved by several methods, including quantification of cardiac biomarkers, 2-dimensional (2D) echocardiographic estimation of LV ejection fraction (EF) and wall motion score index (WMSI), and contrast-enhanced magnetic resonance imaging. Although measurement of creatinine kinase or troponin T levels is widely available, their accuracy to predict LV remodeling is modest. 4, 5 Alternatively, contrast-enhanced magnetic resonance imaging can accurately quantify the extent of myocardial scarring after myocardial infarction and has become the new gold standard for infarct size assessment in many randomized clinical trials. However, this imaging technique is not available at the bedside and may not be feasible in some patients. In contrast, echocardiography is widely available in the acute setting and thus has become the imaging technique of first choice for risk stratification after myocardial infarction. LVEF and WMSI measured early after STEMI are valid surrogates of infarct size and have become established predictors of LV remodeling and clinical outcome. 2, 6 However, several limitations exist in the quantification of these parameters by 2D echocardiography, including the assumption of symmetrical LV geometry, intraobserver and interobserver variability, and, in the case of WMSI, the requirement for expert observers.
Clinical Perspective on p 81
Novel echocardiographic imaging techniques such as speckle-tracking strain imaging provide information on myocardial tissue function, which is incremental to LVEF and WMSI to predict LV functional recovery and clinical outcome after STEMI. 7, 8 LV global longitudinal strain (GLS) measurement after STEMI has also demonstrated specific benefit compared with LVEF in evaluation of the extent of post-STEMI LV myocardial injury. 9, 10 However, despite being proposed as a novel marker of infarct size, few studies have specifically investigated the relationship between baseline LVGLS and LV remodeling in the contemporary post-STEMI population. The aim of the current evaluation was to investigate whether LVGLS measurement before discharge predicts LV dilatation at 3 and 6 months after infarction in a large contemporary STEMI population.
Methods

Patient Population
Patients admitted with a first STEMI treated with primary percutaneous coronary intervention from February 2004 to December 2008 and included in an ongoing registry were evaluated. 11 All patients were treated according to the institutional MISSION! protocol based on the recent guidelines. 12, 13 This clinical framework includes optimal guidelines-based medical therapy, 2D echocardiography performed within 48 hours after primary percutaneous coronary intervention, and standardized outpatient follow-up. Baseline 2D echocardiography was used to assess LV function after STEMI with traditional parameters (LV volume-based indices and WMSI). Speckle-tracking analysis was used to calculate LVGLS at baseline, and patients were divided into 2 groups based on the median value. Two-dimensional echocardiography was repeated at 3-and 6-month follow-up, and the independent association between LVGLS groups and increase in LV end-diastolic volume (EDV) was assessed. Patients who died during index hospitalization or who were in cardiogenic shock requiring inotropic or mechanical circulatory support or in atrial fibrillation at time of baseline echocardiography were excluded. Finally, patients with reinfarction before 6-month echocardiography were also excluded.
Clinical data were prospectively collected in the departmental Cardiology Information System (EPD-Vision, Leiden University Medical Center) and retrospectively analyzed. For this retrospective analysis of clinically acquired data, the institutional review board waived the need for patients' written informed consent.
Two-Dimensional Transthoracic Echocardiography
Patients were imaged in the left lateral decubitus position using a commercially available system (Vivid 7, GE Healthcare; Horten, Norway) equipped with a 3.5-MHz transducer. Analysis of echocardiographic images was performed offline using EchoPAC version 11.0.0 software (GE Healthcare). LV end-systolic volume, LVEDV, and LVEF were quantified at baseline and at 3-and 6-month follow-up using the Simpson biplane technique. 14 The intraobserver and interobserver agreement for assessment of LVEDV at our laboratory has been previously reported as 93% and 92%, respectively. 15 Qualitative assessment of regional wall motion was performed for each patient by dividing the LV into 16 segments. Each segment was then scored individually based on its motion and systolic thickening (1=normokinesis, 2=hypokinesis, 3=akinesis, 4=dyskinesis), and WMSI was calculated as the sum of the segment scores divided by the number of segments scored. 14 Severity of mitral regurgitation was graded according to current recommendations. 16 Diastolic function was assessed according to standard recommendations. 17 Left atrial volume was evaluated with the biplane Simpson technique and indexed to body surface area. 14
GLS Analysis
LVGLS was quantified from the apical 4-, 2-, and 3-chamber views stored as digital cine-loops and processed offline using commercially available speckle-tracking analysis software (EchoPac 112.0.1, GE Medical Systems; Horten, Norway). Images were recorded with frame rates of >40 frames per second to ensure reliable analysis by the software. The end-systolic frame was defined in the apical longaxis view by marking the closure of the aortic valve. After this, the LV endocardial border was traced at end systole in all 3 apical views, and the automatically created region of interest was manually adjusted to the thickness of the myocardium. Tracking quality was assessed in all segments, and if tracking was of poor quality, segments were discarded. LVGLS was provided by the software as the average value of the peak systolic longitudinal strain of the 3 apical views, using a 17-segment model, in a bull's-eye plot ( Figure 1 ). As previously reported, the intraobserver and interobserver variability for the measurement of LVGLS in our institution was 0.1±2.2% and 0.2±0.8%, respectively. 18
Statistical Analysis
Continuous, normally distributed variables are presented as mean and standard deviation or standard error, as appropriate. Nonnormally distributed data are presented as median and interquartile range. Categorical variables are presented as frequencies and percentages. The total population was divided into 2 groups based on the median value of LVGLS. Continuous variables were compared between the 2 groups using the Student t test, Mann-Whitney U test, or χ 2 test, as appropriate.
The primary modeling approach was linear mixed-effects model analysis, with LVEDV as the dependent variable and time (0, 3, and 6 months) as the principal fixed effect. The main predictor variable of interest was baseline LVGLS. Of note, missing data points did not exclude subjects from the analysis as inherent in the mixed modeling analysis structure. To determine whether baseline LVGLS was associated with subsequent change in LVEDV, it was modeled in an interaction term with time. If this group-time interaction term was significant, it indicated a time-dependent relationship between baseline GLS and LVEDV. Post hoc testing was then performed to determine the time points at which LVEDV differed between the LVGLS groups. Other important and potentially confounding baseline clinical and echocardiographic predictors known to influence outcome and LV systolic function after STEMI were similarly tested for their ability to predict change in LVEDV over time. The effect of baseline LVGLS on change in LVEDV was also adjusted for these parameters.
In addition, to evaluate the incremental value of LVGLS compared with clinical and conventional echocardiographic variables in predicting LV dilatation after STEMI, likelihood ratio test and net reclassification improvement index were performed. 19 Net reclassification improvement was used to evaluate the incremental value of baseline LVGLS in reclassifying the risk of individuals developing ≥20% increase in LVEDV 6-months after STEMI. 20 To assess robustness of our initial model, sensitivity analysis was performed, excluding those patients who had died and those who did not have either 3-or 6-month or both echocardiographic data sets available for the initial analysis.
All statistical tests were 2-sided, and a value of P <0.05 was considered statistically significant. Statistical analysis was performed using STATA version 11 (STATA Corp; College Station, TX). The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the article as written.
Results
Baseline Characteristics
Of the 1245 patients initially evaluated, 102 (8%) were excluded because of previous myocardial infarction. Twentytwo (2%) patients died during index hospitalization. An additional 30 patients were excluded because of cardiogenic shock (n=10; 1%) or atrial fibrillation at the time of baseline echocardiography (n=20; 2%). Of the remaining 1091 patients, baseline LVGLS measurement was not possible because of inadequate image quality and too low frame rate in 23 patients (2%). Reinfarction before 6 months had subsequently occurred in 2.5% (n=27) of these patients, and after their exclusion, the final study population comprised 1041 patients ( Figure I in the Data Supplement). Table 1 summarizes the baseline characteristics of the patient population (mean age, 60±12 years; 76% men).
Baseline LVGLS
Median LVGLS was −15.0% (interquartile range, −12.1% to −18.0%) for the total population. Baseline characteristics according to LVGLS >−15.0% (n=520) and ≤−15.0% (n=521) are shown in Table 1 . Patients with LVGLS >−15.0% more frequently had diabetes mellitus, the left anterior descending artery as the culprit vessel, multivessel disease, and higher cardiac biomarker concentrations compared with patients with LVGLS ≤−15.0%. On echocardiography, patients with LVGLS >−15.0% had significantly larger LV volumes and WMSI and lower LVEF compared with their counterparts. Regarding diastolic parameters, E/E′ ratio was significantly higher, and E/A ratio, deceleration time, and E′ were significantly lower in patients with LVGLS >−15.0%. Presence of grade ≥2 mitral regurgitation or left atrial volume index did not differ significantly between the 2 groups.
Follow-Up
Across the total patient population, LVEDV increased significantly between baseline and 3-and 6-month follow-up (from 103±34 to 115±41 and to 112±40 mL, respectively; P<0.001), whereas LV end-systolic volume did not change significantly overall (from 55±22 to 57±29 and to 54±29 mL, respectively; P=0. 21) . In addition, the number of patients showing grade ≥2 mitral regurgitation over length of followup also increased significantly (from 6.0% to 7.9% and to 7.7%, respectively; P=0.006). Table 2 details the results of linear mixed model analyses.
Predictors of Change in LVEDV From Baseline to Follow-Up
Higher WMSI was significantly associated with LV remodeling, as were male sex, left anterior descending artery infarct compared with non-left anterior descending artery, higher discharge heart rate and peak troponin concentration, and lower LAVI at baseline. Regarding LVGLS, although baseline LVEDV was higher in patients with baseline LVGLS >−15.0% compared with ≤−15.0%, this difference was nonsignificant after adjustment for other relevant baseline clinical characteristics (P=0.1). In addition, patients with baseline LVGLS >−15.0% exhibited greater LV dilatation at 3 and 6 months (LVEDV 124±44 versus 106±36 mL; P<0.001 and 121±43 versus 102±34 mL; P<0.001, respectively; group-time interaction term P<0.001) compared with their counterparts. This association between LVGLS and increased LV dilatation retained the same statistical significance after adjustment for all parameters significantly different between GLS groups, in addition to other parameters considered clinically significant (Figure 2) .
On likelihood ratio test, LVGLS (according to median) provided significant incremental value for the prediction of Finally, the analysis was performed after excluding patients who did not have both echocardiographic data sets available for the initial analysis (n=144). In the remaining large subgroup (n=897), the adjusted group-time interaction term P value for this sensitivity analysis remained <0.001.
Discussion
The present observational study shows that in the acute phase after STEMI, stratifying patients according to median LVGLS (−15.0%) delineates a group of patients more likely to show increased LV dilatation at follow-up. LVGLS >−15.0% was independently associated with significantly larger LV volumes during both 3-and 6-month follow-up. In addition, baseline LVGLS provided incremental value to a model containing peak troponin concentration and WMSI to predict LVEDV increase after STEMI.
LVGLS as a Marker of Infarct Size
Speckle-tracking-derived LVGLS is a novel parameter of LV function, which more closely reflects intrinsic myocardial function than traditional parameters by evaluating the active component of deformation. 21 Further, speckle-trackingderived LVGLS is independent of geometric assumptions and insonation angle and has relatively low intraobserver and interobserver variability. 22 Because of these inherent GLS indicates global longitudinal strain; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; and WMSI, wall motion score index.
*P values represent the covariate-time interaction term; if significant (P<0.05), it indicates a time-dependent relationship between LVEDV and the particular covariate. advantages compared with other echocardiographic modalities, several recent studies have investigated the role of LVGLS measurement as a marker of infarct size, whether measured in the acute phase after revascularization 9,10,23 or at followup. 24, 25 A cutoff for LVGLS of −15% measured after reperfusion served as a more precise predictor of large infarction than LVEF in 39 thrombolysis-treated patients with STEMI. 9 In a larger group of primary percutaneous coronary interventiontreated patients, LVGLS measured at day 1 was also superior to LVEF in predicting 30-day infarct size. 23 In our large population of contemporary STEMI patients treated with primary percutaneous coronary intervention, a postrevascularization LVGLS value >−15.0% was significantly associated with clinical characteristics traditionally indicative of larger infarct size (diabetes mellitus, multivessel disease, and higher biomarker levels). In addition, these patients had significantly more impaired global and regional systolic and diastolic function parameters (including LVEF, WMSI, and E′) compared with the group of patients with more preserved myocardial shortening (LVGLS ≤−15.0%).
LVGLS and LV Remodeling
Despite the demonstrated role of LVGLS in accurately identifying the extent of global myocardial injury and dysfunction after infarction, few studies in the contemporary era have specifically related LVGLS measurement in the acute phase after STEMI to the risk of LV remodeling at follow-up. A substudy of the Valsartan in Acute Myocardial Infarction Trial (VAL-IANT) study, including 603 post-STEMI patients with LV dysfunction, demonstrated no significant association between myocardial longitudinal strain rate and LV remodeling. 26 However, those patients were enrolled before the systematic use of primary percutaneous coronary intervention and other current guideline-based antiremodeling therapies. Studies involving modern era patients with STEMI, which have demonstrated an association between LVGLS and LV remodeling, are limited by small numbers, variable LV remodeling definitions, and shorter follow-up periods. 27, 28 The current evaluation considerably expands on previous studies by relating baseline LVGLS measurement in a large cohort of contemporary STEMI patients to accepted echocardiographic outcomes on systematic 3-and 6-month follow-up. Patients with LVGLS >−15% were significantly more likely to display pathological LV dilatation at both 3 and 6 months after STEMI. This relationship remained significant even after adjusting for multiple clinical parameters known to influence post-STEMI outcome. Importantly, repeating the analysis per quartile of GLS (Data Supplement) showed a stepwise relationship between less negative (more impaired) GLS and progressive LV dilatation, with the greatest and most significant increase in LVEDV at both 3 and 6 months occurring in those patients in the highest quartile of GLS (>−12.1%). The finding that LVGLS measurement before discharge can identify patients at increased risk of LV dilatation is particularly relevant, given that it can be quantified at rest and without need for pharmacological stressors, expensive contrast media, or exposure to ionizing radiation.
LVGLS Versus WMSI in Risk Stratification After STEMI
Previous studies have consistently shown that WMSI evaluation is superior to LVEF for early risk assessment after STEMI. 6, 29 WMSI and LVGLS were recently shown to accurately identify substantial infarction in non-STEMI patients before revascularization. 30 However, segmental motion, and thus WMSI, unlike LVGLS, may be influenced by tethering of scar tissue by adjacent viable myocardium. In the current study, we confirmed an advantage of LVGLS compared with WMSI for early risk stratification after STEMI. Although baseline WMSI was independently associated with LV remodeling at 3-and 6-month follow-up, the addition of LVGLS to a model containing WMSI provided incremental value for prediction of LVEDV increase. Although the absolute differences in LVEDV at follow-up seem small, LVGLS was both incremental to WMSI and significantly reclassified additional patients over and above traditional post-STEMI risk parameters. Given these findings and the fact that LVGLS provides a semiautomated, quantitative measure of LV systolic function, its future use for risk stratification in all patients with STEMI is highly foreseeable.
Limitations
This was a retrospective evaluation. However, it reports prospectively collected real-world data on a large cohort of modern-era patients with STEMI treated optimally according to a dedicated, guideline-based protocol. 11 Patients in cardiogenic shock requiring supportive therapy were not included in this study; therefore, these findings may not apply to this important patient group. However, these patients represent a high-risk group, and additional strategies for risk stratification are less clinically relevant. In addition, echocardiography was performed within 48 hours after STEMI in all patients; the dynamic nature of LV function recovery after STEMI may lead to an underestimation of the systolic function during this time period. However, in the final adjusted model, time from reperfusion to baseline echocardiography did not have a significant effect on the relationship between baseline LVGLS and follow-up LV dilatation. 2, 6 Two-dimensional Simpson biplane method to assess LVEDV may be less accurate in the presence of foreshortening or irregular LV geometry and is associated with a high variability. 31 However, the prognostic value of LVEDV using this method of assessment has been proven, 32 and it remains the currently recommended method to assess LV systolic function on 2D echocardiography. 14 Changes in heart rate during followup and their association with LV dilatation were not assessed. However, the aim of the current study was to assess the effect of LVGLS measured in the acute phase after STEMI on followup LV dilatation compared with other baseline characteristics (including discharge heart rate) known to influence later risk of remodeling. In addition, changes in medication at follow-up were not systematically recorded. However, it is known from a systematic overview of angiotensin-converting enzyme inhibition in patients with STEMI that most of the survival benefit is observed in the first week. 33, 34 Intraobserver and interobserver variability measurements were not performed as part of the current study protocol. However, our laboratory performs LVGLS measurements in a standardized manner. The reproducibility measurements for GLS from our laboratory were recently reported in a similar patient cohort to the current study population. 18 Finally, contrast-enhanced magnetic resonance imaging would have been desirable to strengthen our observations on LVGLS and its relation to infarct size and subsequent LV remodeling. However, LVGLS provided significant incremental value to other established parameters of infarct size, including peak troponin concentration and WMSI, for the prediction of LV dilatation at follow-up.
Conclusions
Stratifying patients with STEMI according to median value of LVGLS on baseline echocardiography may serve as an additional marker of infarct size. Further, LVGLS before discharge after STEMI was an independent predictor of LV dilatation at both 3-and 6-month follow-up. This large contemporary registry study confirms the benefit of this quick, inexpensive, and widely available tool for risk stratification after STEMI.
